EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY-NC 4.0

Development and Validation of a CT-Based Intratumoral-Peritumoral Radiomics Signature for Tumor Mutational Burden Prediction with Prognostic Implications in Non-Small Cell Lung Cancer: A Multicenter Study

Huaxin Li, Ruotong Wu iD, Qingqing Hui, Lu Zhang, Wei Du, Hua Wang, Zhaoxiang Ye

Technology in Cancer Research & Treatment · 2026-08 · 25

DOI: 10.1177/15330338261500562 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 03.11.2026. Verfasst von Huaxin Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggab…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tianjin Key Medical Discipline (Specialty) Construction Project, National Natural Science Foundation of China, Tianjin Municipal Health Commission Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

To develop and validate an intratumoral–peritumoral CT radiomics signature for predicting tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC) and assess its prognostic value in advanced NSCLC treated with immune checkpoint inhibitors (ICIs). The proposed TMB classifier aims to support noninvasive patient stratification and guide clinical decision-making regarding molecular testing and immunotherapy selection.

Methods

In this multicenter retrospective study, the TMB prediction cohort comprised 380 patients (training set, n=228; validation set, n=97; external testing set, n=55), and 65 patients receiving ICIs formed an independent immunotherapy validation cohort. Intratumoral (T-Rad) and peritumoral (P3-, P5-, P7-Rad) models were constructed after feature selection. Each peritumoral model was fused with T-Rad to generate F3-, F5-, and F7-Rad models. Radiomics features were integrated with independent clinical predictors to establish a combined model. The predicted probability (Rad_signature) from the optimal fused model was evaluated for prognostic value. Gene enrichment analysis was performed in 89 NSCLC patients from The Cancer Imaging Archive (TCIA) database to investigate the biological basis of the Rad_signature.

Results

The F5-Rad model significantly outperformed the T-Rad with AUCs of 0.827 (95%CI: 0.761-0.892), 0.785 (95%CI: 0.687-0.882), and 0.756 (95%CI: 0.581-0.931) in the training, validation, and external testing sets (P = 0.017, 0.041, and 0.024). The combined clinical-radiomics model achieved the highest AUCs of 0.888 (95%CI: 0.839-0.937), 0.825 (95%CI: 0.742-0.907), and 0.765 (95%CI: 0.592-0.938), respectively. In the immunotherapy cohort, Rad_signature (HR = 0.483, 95%CI: 0.236-0.990, P = 0.047) served as an independent prognostic factor for progression-free survival and demonstrated good calibration at 6, 12, and 24 months. Gene Ontology analysis highlighted chromosome segregation and mitotic processes, while gene set enrichment analysis identified cell cycle and proliferation-related pathways, particularly E2F targets and G2M checkpoint.

Conclusions

A CT-based radiomics signature enables noninvasive TMB prediction and provides prognostic relevance in NSCLC patients receiving immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationRadiomicsTomography, X-Ray ComputedAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective Studies

Stichwörter der Autor:innen

Computed tomographyImmunotherapyNon-small cell lung cancerRadiomicsTumor mutational burden

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiology, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory…
  • Department of Diagnostic Radiology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
  • Center for Precision Cancer Medicine and Translational Research, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.

ORCID-Profile: Ruotong Wu

Förderung

  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • National Natural Science Foundation of China
  • Tianjin Municipal Health Commission Science and Technology Project

Zitieren

APA

Li, H., Wu, R., Hui, Q., Zhang, L., Du, W., Wang, H., & Ye, Z. (2026). Development and Validation of a CT-Based Intratumoral-Peritumoral Radiomics Signature for Tumor Mutational Burden Prediction with Prognostic Implications in Non-Small Cell Lung Cancer: A Multicenter Study. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261500562

Vancouver

Li H, Wu R, Hui Q, Zhang L, Du W, Wang H, et al. Development and Validation of a CT-Based Intratumoral-Peritumoral Radiomics Signature for Tumor Mutational Burden Prediction with Prognostic Implications in Non-Small Cell Lung Cancer: A Multicenter Study. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261500562

BibTeX
@article{Li2026,
  author = {Li, Huaxin and Wu, Ruotong and Hui, Qingqing and Zhang, Lu and Du, Wei and Wang, Hua and Ye, Zhaoxiang},
  title = {Development and Validation of a CT-Based Intratumoral-Peritumoral Radiomics Signature for Tumor Mutational Burden Prediction with Prognostic Implications in Non-Small Cell Lung Cancer: A Multicenter Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261500562}
}
Kostenlos starten →